MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijantimicag.2024.107164

Медицинская библиотека · International journal of antimicrobial agents · 2024

Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.

Hidalgo-Tenorio Carmen, Sequera Sergio, Vivancos María Jesus, Vinuesa David, Collado Antonio, Santos Ignacio De Los, Sorni Patricia, Cabello-Clotet Noemi, Montero Marta, Font Carlos Ramos, Terron Alberto, Galindo Maria José, Martinez Onofre, Ryan Pablo, Omar-Mohamed Mohamed, Albendín-Iglesias Helena, Javier Rosario, Ruz Miguel Ángel López-, Romero Alberto, Garcia-Vallecillos Coral

СтатьяМногоцентровое исследованиеКлиническое исследование IV фазыПеревод в очереди

Аннотация

OBJECTIVE

Multiple strategies have been utilised to reduce the incidence of HIV, including PrEP and rapid antiretroviral therapy initiation. The study objectives were to evaluate the efficacy, safety, satisfaction, treatment adherence, and system retention obtained with rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in naïve patients.

METHODS

This phase IV, multicenter, open-label, single-arm, 48-week clinical trial enrolled patients between January 2020 and June 2022. Adherence to treatment was evaluated with the SMAQ questionnaire and patient satisfaction with the EQ-5D.

RESULTS

Two hundred eight participants were enrolled with mean age of 35.6 years; 87.6% were males; mean CD4 count was 393.5 cells/uL (<200 cells/uL in 22.1%); viral load log was 5.6 (VL>100 000 cop/mL in 43.3%); 22.6% had AIDS, and 4.3% were coinfected with HBV. BIC/FTC/TAF was initiated on the day of their first visit to the HIV specialist in 98.6% of participants, and 9.6% were lost to follow-up. The efficacy at week 48 was 84.1 % by intention-to- treat (ITT), 94.6% by modified ITT, and 98.3% by per protocol analysis. The regimen was discontinued in two subjects (0.9%) during week 1 for grade 3 adverse events. Treatment adherence (weeks 4 [90%, IQR: 80-99%] vs. 48 [90%, IQR: 80-95%; P = 0.49]) and patient satisfaction (weeks 4 [90%, IQR: 80-99%] vs. 48 [90%, IQR: 80-95 P = 0.49]) rates were very high over the 48- week study period.

CONCLUSIONS

BIC/FTC/TAF is an appropriate option for rapid ART initiation in naïve HIV patients, offering high efficacy, safety, durability, treatment adherence, retention in the healthcare system, and patient satisfaction. Number Clinical Trial registration: NCT06177574.

Для цитирования: Hidalgo-Tenorio Carmen, Sequera Sergio, Vivancos María Jesus, Vinuesa David, Collado Antonio, Santos Ignacio De Los, Sorni Patricia, Cabello-Clotet Noemi, Montero Marta, Font Carlos Ramos, Terron Alberto, Galindo Maria José, Martinez Onofre, Ryan Pablo, Omar-Mohamed Mohamed, Albendín-Iglesias Helena, Javier Rosario, Ruz Miguel Ángel López-, Romero Alberto, Garcia-Vallecillos Coral. Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.. International journal of antimicrobial agents. 2024. DOI: 10.1016/j.ijantimicag.2024.107164.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.